Mersana Therapeutics (MRSN) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Mersana Therapeutics (NASDAQ:MRSN) from a hold rating to a buy rating in a research report report published on Thursday morning. The brokerage currently has $20.00 price objective on the stock.

According to Zacks, “Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company’s product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States. “

How to Become a New Pot Stock Millionaire

Other equities analysts have also recently issued research reports about the company. HC Wainwright assumed coverage on Mersana Therapeutics in a report on Thursday, February 15th. They set a buy rating for the company. ValuEngine raised Mersana Therapeutics from a strong sell rating to a sell rating in a report on Friday, February 2nd. Finally, JPMorgan Chase & Co. cut Mersana Therapeutics from an overweight rating to a neutral rating and set a $23.00 target price for the company. in a report on Monday, March 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of Hold and an average target price of $24.80.

Mersana Therapeutics stock opened at $17.80 on Thursday. Mersana Therapeutics has a fifty-two week low of $12.45 and a fifty-two week high of $21.01.

Institutional investors have recently made changes to their positions in the business. TIAA CREF Investment Management LLC raised its holdings in shares of Mersana Therapeutics by 1,132.7% during the fourth quarter. TIAA CREF Investment Management LLC now owns 8,037 shares of the company’s stock valued at $132,000 after acquiring an additional 7,385 shares during the last quarter. California State Teachers Retirement System acquired a new position in shares of Mersana Therapeutics during the third quarter valued at approximately $142,000. Candriam Luxembourg S.C.A. acquired a new position in shares of Mersana Therapeutics during the fourth quarter valued at approximately $197,000. Bank of New York Mellon Corp acquired a new position in shares of Mersana Therapeutics during the third quarter valued at approximately $231,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Mersana Therapeutics during the fourth quarter valued at approximately $247,000. 75.73% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Mersana Therapeutics (MRSN) Stock Rating Upgraded by Zacks Investment Research” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3299509/mersana-therapeutics-mrsn-stock-rating-upgraded-by-zacks-investment-research.html.

About Mersana Therapeutics

Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.

Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Liberum Capital Reiterates Hold Rating for Sports Direct
Liberum Capital Reiterates Hold Rating for Sports Direct
RWS  Rating Reiterated by Shore Capital
RWS Rating Reiterated by Shore Capital
WPP’s  Hold Rating Reiterated at Deutsche Bank
WPP’s Hold Rating Reiterated at Deutsche Bank
Berenberg Bank Raises Ten Entertainment Group  Price Target to GBX 310
Berenberg Bank Raises Ten Entertainment Group Price Target to GBX 310
Evonik Industries  Given a €27.00 Price Target by UBS Analysts
Evonik Industries Given a €27.00 Price Target by UBS Analysts
eMagin  Sees Large Decline in Short Interest
eMagin Sees Large Decline in Short Interest


© 2006-2018 Ticker Report. Google+.